- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 263/34 - Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
Patent holdings for IPC class C07D 263/34
Total number of patents in this class: 258
10-year publication summary
23
|
15
|
21
|
16
|
18
|
15
|
16
|
20
|
13
|
9
|
2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Theravance Biopharma R&D IP, LLC | 458 |
27 |
Pro Farm Group, Inc. | 119 |
10 |
DSM IP Assets B.V. | 5591 |
8 |
Siemens Medical Solutions USA, Inc. | 1515 |
7 |
Astellas Pharma Inc. | 1088 |
6 |
Boehringer Ingelheim International GmbH | 4650 |
5 |
Takeda Pharmaceutical Company Limited | 2713 |
5 |
Nippon Shinyaku Co., Ltd. | 325 |
5 |
Arizona Board of Regents on behalf of Arizona State University | 2625 |
4 |
Blade Therapeutics, Inc. | 19 |
4 |
Kissei Pharmaceutical Co., Ltd. | 183 |
4 |
Otsuka Pharmaceutical Co., Ltd. | 1493 |
4 |
AstraZeneca AB | 2909 |
3 |
Janssen Pharmaceutica N.V. | 3392 |
3 |
Merck Patent GmbH | 5831 |
3 |
Syngenta Crop Protection AG | 6054 |
3 |
Allergan, Inc. | 2349 |
3 |
Bayer Pharma AG | 1052 |
3 |
Amgen Inc. | 4074 |
3 |
Beiersdorf AG | 3014 |
3 |
Other owners | 145 |